Terran Biosciences, a private biotech firm, has signed a licensing deal with pharmaceutical giant Sanofi (NASDAQ: SNY).
The company’s press release was short on specifics, but Terran Biosciences has obtained a worldwide exclusive license to a portfolio of Sanofi’s Phase 3 CNS therapeutics. According to the announcement, the therapeutics included in this deal have generated “4 Investigational New Drug (IND) applications and over 104 clinical studies involving more than 15,000 subjects across a number of CNS indications”.
Terran has been low-key about their developments, but have recently announced moves like an acquisition of a portfolio of novel CNS therapeutics from Concert Pharmaceuticals, an exclusive licensing deal for a portfolio of patents and data in the psychedelic therapeutic space, and another licensing deal with Columbia University for exclusive rights to CNS biomarker software. There was also a recent deal for Terran to acquire the full patent portfolio from a pioneer of psychedelics research.
Microdose reached out to Valhalla Ventures, an early investor in Terran.
Terran is developing some of the most innovative assets and IP in the space. For example, Jordi Ribas’ work as an early pioneer of ayahuasca and psychedelic research was groundbreaking. He made discoveries that have the potential to transform psychedelic-based medicines and make them more accessible to the people who need them most.
Terran is uniquely positioned to take this work forward as they have both classic and novel psychedelics and the largest medicinal chemistry program which has created some of the most important improvements to the classical psychedelics. For example, they solved the main problem limiting the use of DMT which is that it lacks oral activity. Beyond what other companies are working on including injected, inhaled, buccal, or sublingual, Terran’s scientists created an entirely new invention, the world’s first orally active DMT and 5-Meo-DMT that can be ingested and reaches full effects without an monoamine oxidase (MAO) inhibitor.
We were not surprised that Sanofi chose to partner with Terran as Terran is one of the few companies applying biotech principles to the development of psychedelics and have a unique approach to solving many of the challenges limiting the use of psychedelics in the clinic….Terran is not only a psychedelics company, they also have a number of late-stage therapeutics in classical neuropsych indications. Not all of these have been disclosed and we expect some big announcements in the near future. We look at Terran, not as another psychedelics company, but rather more akin to the large neuro platform companies, Cerevel and Neumora.
We are incredibly excited about the team and their technology and can’t wait to watch their success!
See the press release below and stay tuned to Microdose for more on this.
Terran Biosciences announces licensing deal with Sanofi for two late-stage CNS pipeline assets
NEWS PROVIDED BY
21 Apr, 2022, 15:38 IDT
- Terran to advance the development of two of Sanofi’s Phase 3 CNS therapeutics
- Transaction includes worldwide exclusive rights for development and commercialization in all fields of use
NEW YORK, April 21, 2022 /PRNewswire/ — Terran Biosciences, Inc. (“Terran”), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has entered into an agreement with Sanofi S.A. (“Sanofi”) for worldwide exclusive rights to develop and commercialize two late-stage CNS pipeline assets.
These therapeutics generated 4 Investigational New Drug (IND) applications and over 104 clinical studies involving more than 15,000 subjects across a number of CNS indications.
Terran plans to quickly advance the development of these assets for neurological and psychiatric indications, which include several novel applications where there is a large unmet medical need. This transaction represents the key next stage in the development of these promising assets.
The deal included an upfront payment as well as typical success-based milestones and royalties. Specific financial terms of the deal were not disclosed.
“We are grateful to the Sanofi team for entrusting us to continue the development of these late-stage therapeutics, which we believe have the potential to transform the paradigm in neuropsychiatry,” stated Dr. Sam Clark, Terran’s Founder and CEO.
About Terran Biosciences, Inc.
Terran is a biotech platform company developing a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases. Backed by a number of life-science and tech investors, Terran has built a CNS-focused, tech-enabled drug development platform, and is rapidly advancing of number of late-stage assets, which include novel psychedelic-based therapeutics.
Terran Contact
Investor Relations:
ir@terranbiosciences.com
Media:
info@terranbiosciences.com
